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Abstract
Although chemotherapy is used to treat most advanced solid tumors, recurrent disease is still the major cause of cancer-
related mortality. Cancer stem cells (CSCs) have been the focus of intense research in recent years because they provide a
possible explanation for disease relapse. However, the precise role of CSCs in recurrent disease remains poorly understood
and surprisingly little attention has been focused on studying the cells responsible for re-initiating tumor growth within the
original host after chemotherapy treatment. We utilized both xenograft and genetically engineered mouse models of non-
small cell lung cancer (NSCLC) to characterize the residual tumor cells that survive chemotherapy treatment and go on to
cause tumor regrowth, which we refer to as tumor re-initiating cells (TRICs). We set out to determine whether TRICs display
characteristics of CSCs, and whether assays used to define CSCs also provide an accurate readout of a cell’s ability to cause
tumor recurrence. We did not find consistent enrichment of CSC marker positive cells or enhanced tumor initiating potential
in TRICs. However, TRICs from all models do appear to be in EMT, a state that has been linked to chemoresistance in
numerous types of cancer. Thus, the standard CSC assays may not accurately reflect a cell’s ability to drive disease
recurrence.
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Introduction
The identity and properties of cancer stem cells (CSCs) has been
a field of intense study in recent years. CSCs have been defined as
having the unique capability to both self renew and give rise to
differentiated progeny in serial transplantation assays [1]. The
isolation of CSCs based on distinct surface marker expression has
been reported for numerous hematologic malignancies and solid
tumors [2]. Several groups have reported that CSCs show
enhanced resistance to conventional chemotherapeutic agents
and radiation treatment [3–8]. Thus, it has been hypothesized that
CSCs are inherently resistant to chemotherapy and as such
responsible for disease relapse.
For most cancers, disease relapse after chemotherapy is a major
cause of mortality. Thus, a better understanding of the cells that
cause recurrence, which we call tumor re-initiating cells (TRICs),
could have a major impact on our ability to effectively treat
patients. This is particularly relevant for non-small cell lung cancer
(NSCLC) because more than two thirds of patients are not
candidates for surgical resection. Most patients present with
advanced disease and are treated with chemotherapy, radiation or
a combination of the two [9]. However, despite aggressive
treatment the five-year survival rate for NSCLC remains at
17.5% [10]. Although CSCs have been characterized in many
different cancers [11], they remain ill-defined in NSCLC [12].
Moreover, conflicting reports on the use of cell surface markers to
isolate CSCs from NSCLC tumors leave their identity uncertain
[13–17]. Finally, it is unclear how the ability of purified cell
populations to initiate new tumors in a naı¨ve host, the gold-
standard CSC assay, relates to the maintenance of tumor growth
or tumor relapse in a patient.
We identified several NSCLC models whose tumors regress
upon treatment with standard of care chemotherapy. Despite
significant cytoreduction, the residual tumors in each of these
models re-grew after the cessation of therapy. As such, the residual
tumor cells that survive chemotherapy treatment in these models
must be the cells responsible for disease relapse and we refer to
them from here on as TRICs. We isolated TRICs from each of
these models and assessed them for their CSC properties using
surface marker and gene expression analysis and serial transplan-
tation assays. Our data show that TRICs do not consistently meet
criteria typically used to define CSCs, but are indeed in a state of
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epithelial to mesenchymal transition (EMT), which has previoiusly
been attributed to both stemness and drug-resistance [18,19].
Materials and Methods
Cell Culture
Calu3, H441 and H596 human NSCLC cell lines were
obtained from American Type Culture Collection (ATCC),
Manassas, VA. To generate GFP expressing stable cell lines,
Calu3, H441 and H596 cell lines were transduced with TZV-b-
actin-eGFP lentivirus. After multiple passages, the 20% highest
GFP expressing cells were sorted, amplified and preserved for
further studies. These sub-lines were described as Calu3-GFP,
H441-GFP and H596-GFP.
Sphere formation assays. To determine the sphere forming
potential of TRICs, tumors were dissociated and GFP+ cells were
collected by FACS. Cells were resuspended in N5 media at a
concentration of 40 cells/ul. The cell suspension was mixed 1:1
with matrigel (BD Biosciences) and 100 ul/well of the cell/
matrigel solution was plated into 96 well plates. Plates were
incubated at 37uC for 30–60 minutes to allow solidification of the
matrigel, then overlayed with 100 ul of N5 media. Cells were
cultured for 7 days at 37uC then assessed for sphere formation. N5
media consisted of DMEM/F12 (+HEPES/glutamine), 5% FBS,
bovine pituitary extract (35 ug/ml), N2 supplement, antibiotic/
antimitotic, EGF (20 ng/ml) and FGF (20 ng/ml).
Generation of Donor Xenograft Tumors
All animal experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) at Genentech Inc.
Athymic nude mice were housed and maintained in pathogen-free
conditions. To generate tumors, suspensions of freshly passaged
tumor cells (15–20 million) were transplanted subcutaneously into
the right flank of athymic nude mice. When tumors reached
,150–250 mm3, the mice were divided into different treatment
groups. Mice were then treated with either vehicle or chemother-
apy (paclitaxel, i.v. + cisplatin, i.p.). The chemotherapy-dosing
regimen was paclitaxel 20 mg/kg i.v. every other day for 5 doses,
and cisplatin 5 mg/kg i.p. on days 1 and 7 for the Calu3 model,
days 1 and 14 for the H441 model, and days 1, 7 and 14 for the
H596 model. Regressed tumors from chemo-treated and time
matched tumors from vehicle-treated control mice were collected
at least 1 week after the last dose of chemotherapy. Tumors were
minced and dissociated using dispase/collagenase. Propidium
iodide (PI) was used to exclude dead cells and GFP+ tumor cells
were sorted using FACSVantage and FACSAria (BD Biosciences).
Flow Cytometric Analysis
GFP+ tumor cells isolated from vehicle and chemo-treated mice
at regression were stained with CD133-APC (MACS #130-090-
826), CD44-PE (eBioscience #12-0441-83) and CD117-PEC-Cy7
Figure 1. Characterization of In vivo Models for the Study of
Tumor Re-Initiating Cells (TRICs). (A) Schematic representation of
study design. GFP labeled human tumor cells were transplanted
subcutaneously, and when tumor size reached ,250 mm3 mice were
treated with either vehicle or chemotherapy as shown in the respective
models. GFP+ tumor cells were isolated from regressed or vehicle-
treated tumors by FACS-sorting after enzymatic digestion and
dissociation. Tumors were collected a minimum of one week after the
last dose of chemotherapy and before the resumption of tumor growth.
(B) Growth of vehicle and chemo-treated Calu3-GFP xenograft tumors.
Data presented as mean tumor volume 6 SEM, n = 15/group. (C)
Growth of vehicle and chemo-treated H441-GFP xenograft tumors. Data
presented as mean tumor volume 6 SEM, n = 9/group for vehicle-
treated and n=14/group for chemo-treated. (D) Growth of vehicle and
chemo-treated H596-GFP xenograft tumors. Data presented as mean
tumor volume 6 SEM, n = 10/group for vehicle-treated and n=18/
group for chemo-treated. Each/indicates a mouse euthanized for
analysis. (E) Number of GFP+ tumor cells present in vehicle and
chemo-treated tumors as determined by FACS. Sorting of vehicle-
treated tumor cells was stopped at 500,000 cells for all models.
doi:10.1371/journal.pone.0045647.g001
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(BD Bioscience # 339195) antibodies or appropriate isotype-
matched control antibodies. Samples were analyzed using the
FACScaliber and data was analyzed using FlowJo software.
RNA Isolation, cDNA Preparation and qRT-PCR
RNA was isolated from FACS sorted tumor cells isolated from
vehicle-treated and chemo-treated mice at regression using Qiagen
RNeasy Micro Kit. Complementary DNA was prepared from
total RNA using ABI High capacity cDNA reverse transcription
kit according to manufacturer’s instructions. Expression of
VIMENTIN, ZEB1, ZEB2, SNAI1, SNAI2, TWIST1 and N-
CADHERIN was determined using ABI gene specific primers/
probe by quantitative real time PCR (ABI 7500). Gene expression
was normalized using GAPDH house keeping gene.
Serial Transplantation of Xenograft Tumor Cells to Assess
Tumor Initiating Potential
Propidium iodide (PI)-, GFP+ tumor cells were sorted by FACS
from tumors of vehicle or chemotherapy-treated mice at regression
in Calu3, H441 and H596 models. Cells were counted using
trypan blue staining to exclude dead cells and debris and cell
suspensions were prepared in 1:1 mixture of RPMI and matrigel
(BD Bioscience). These cell suspensions were injected subcutane-
ously into athymic nude mice, with vehicle-treated and chemo-
treated tumor cells being injected into opposite flanks. Tumor
growth was monitored for the amount of time indicated.
Orthotopic Implantation of GEMM Tumor Cells to Assess
Tumor Initiating Potential
Beginning 12 weeks after tumor initiation, LSL-KrasG12D;p53Fl/Fl
mice were treated with cisplatin (7 mg/kg IP) or vehicle once a
week for 3 weeks. Lungs were collected from cisplatin and vehicle-
treated mice one week after the final dose of cisplatin. Lungs were
dissociated and GFP+ tumor cells were collected by FACS. Cells
were counted using trypan blue staining to exclude dead cells and
debris, and equal numbers of vehicle- and chemo-treated tumor
cells were implanted orthotopically via intratracheal intubation.
Lungs were collected 16 weeks later and tumor burden was
assessed by ex vivo micro-CT.
Micro-CT Analysis of Lungs
Mice were euthanized by transcardiac perfusion of PBS under
anesthesia. A cannula was inserted through the trachea. Intact
tumor bearing lungs were dissected, fixed with 10% formalin for
24 hours and further processed as described previously [20]. Lungs
were imaged ex-vivo with a MicroCT 42 (SCANCO Medical,
Basserdorf, Switzerland) x-ray micro-computed tomography (mi-
cro-CT) system. Images were generated by operating the x-ray
Table 1. Tumor initiating potential of TRICs in transplantation assays.
Tumor Model No. of Cells Grafted Treatment
No. Mice
with Tumor
Tumor Volume (mm3)
AVG ± SEM
Calu3-GFP on day 125 500 Vehicle (Left) 1/9 31.4631.4
Chemo (Right) 0/9 0
5000 Vehicle (Left) 4/8 112.7639.7
Chemo (Right) 0/8 0
25000 Vehicle (Left) 6/8 346.36108.2
Chemo (Right) 0/8 0
H441-GFP on day 125 100 Vehicle (Left) 2/5 212.66194.5
Chemo (Right) 0/5 0
1000 Vehicle (Left) 3/5 261.46149.7
Chemo (Right) 3/5 159.4690.1
5000 Vehicle (Left) 5/5 1072.36355.1
Chemo (Right) 4/5 271.66159.1
H596-GFP on day 36 500 Vehicle (Right) 4/7 78.7625.8
Chemo (Left) 6/7 268.3677.2
5000 Vehicle (Right) 6/7 262.8660
Chemo (Left) 6/7 883.86450
22000 Vehicle (Right) 5/7 210.6675.4
Chemo (Left) 5/7 696.56260.8
Tumor Model No. of Cells Grafted Treatment No. Mice with Tumor Tumor Number AVG ± SEM
GEMM on day 112 100 Vehicle 0/17 0
Chemo 3/8 0.660.3
1000 Vehicle 9/19 160.3
Chemo 5/10 0.860.1
5000 Vehicle 17/19 3.360.8
Chemo 9/9 5.861.4
Tumor size .50 mm3 was considered as positive for tumor growth.
doi:10.1371/journal.pone.0045647.t001
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tube at an energy level of 45 kV, a current of 177 mA and an
integration time of 300 milliseconds.
Influence of Stroma on Tumor-initiating Potential
To assess the effect of stroma on tumor initiating potential, four
different cell fractions were isolated from tumors from vehicle- or
chemo-treated mice by FACS sorting tumors from several mice.
The following cell types from were pooled from multiple tumors (1)
GFP+ tumor cells from chemo-treated mice (CT), (2) GFP-
stromal cells from chemo-treated mice (CS), (3) GFP+ tumor cells
from vehicle-treated mice (VT), and (4) GFP- stromal cells from
vehicle-treated mice (VS). Tumor cells and stromal cells were
mixed 1:10 in the combinations indicated, and transplanted
subcutaneously into the left and right flanks of athymic nude mice.
Tumor growth was monitored for the duration indicated.
Immunoflurescence Analysis
For histological evaluation of tumors, tumor tissues were
collected from vehicle- or chemo-treated mice at regression and
relapse and were fixed in formalin. Tissues were paraffin
embedded and cut into 3 uM sections. Immunofluorescence was
performed following Declere dewaxing/unmasking according to
manufacturer’s instructions (Sigma-Aldrich D3565). Chicken-
Anti-GFP (Aves Labs cat# GFP-1020) was used at a 1:500
dilution, Rabbit-anti-E-Cadherin (Cell Signaling cat# 3195) at a
1:75 dilution and Rabbit-anti-Vimentin (clone SP20 Lab Vision
cat# RB-9120-S1) at a 1:200 dilution. Secondary antibodies were
Alexa-488 Goat-anti-Chicken (Invitrogen) at a 1:500 dilution and
Alexa-594 Donkey-anti-Rabbit (Invitrogen) 1:800. Nuclei were
identified by DAPI.
Statistical Analysis
Results are presented as average +/2 SEM, and statistical
significance was determined with an unpaired t test. p,0.05 was
considered as statistically significance.
Results
In vivo Models of NSCLC for the Study of Residual Disease
and Relapse
To characterize a subpopulation of tumor cells that survive
chemotherapy treatment and mediate tumor recurrence, we
Figure 2. Characterization of TRICs for Cancer Stem Cell Potential in vivo. (A) Proportion of CSC-marker positive cells in vehicle and
chemotherapy-treated Calu3, H441 and H596 tumors. Data is presented as average +/2 SEM, n $4 mice per group. (B–D) Tumor forming capacity of
B) Calu3-GFP, C) H441-GFP and D) H596-GFP tumor cells. Cells were isolated from vehicle or chemo-treated mice at tumor regression and grafted
subcutaneously into athymic nude mice. Graphs show indivdual tumor size with bars indicating average tumor volume per group (left) and tumor
incidence (right). Tumors.50 mm3 were considered as positive tumor growth. (E) Tumor forming capacity of GEMM tumor cells isolated from vehicle
or chemo treated mice at tumor regression and grafted orthotopically into athymic nude mice. Graphs show number of tumors per individual mouse
with bars indicating average number (left) and tumor incidence (right). (For further details see also Table 1).
doi:10.1371/journal.pone.0045647.g002
Table 2. Effect of stroma on tumor-initiating potential of TRICs in transplantation assays.
Tumor Model Sl. No. Groups
Tumor Volume (mm3)
AVG ± SEM
No. Mice
with Tumor
Tumor Formation
Frequency (%)
Calu3-GFP on
day 97
1 5k VT + 50 k CS 642.56113.4 9/9 100
2 5k VT + 50 k VS 717.56170.7 9/9 100
3 5k VT 1509.26312.8 9/9 100
4 5k CT + 50 k CS 152.9676.7 5/9 55.5
5 5k CT + 50 k VS 257.8689.7 6/9 66.6
6 5k CT 251.96130.6 4/9 44.4
7 50k VS 103.4655.4 3/9 33.3
8 50k CS 0 0/9 0
9 500 VT + 5 k CS 240.1673.4 7/9 77.7
10 500 VT + 5 k VS 551.96118.8 8/9 88.8
11 500 CT + 5 k CS 1.761.7 0/9 0
12 500 CT + 5 k VS 11.368.3 1/9 11.1
13 5k VS 54.4628.9 3/9 33.3
14 5k CS 0 0/9 0
H441-GFP on
day 139
1 2.5 k VT + 25 k CS 895.36226.6 7/8 87.5
2 2.5 k VT + 25 k VS 958.66243.1 7/9 77.7
3 2.5 k CT + 25 k CS 9.869.8 1/14 7.1
4 25 k VT 603.56304.2 4/8 50
5 25 k CS 0 0/8 0
VT= Tumor cells from vehicle-treated mice, CT = Tumor cells from chemo-treated mice at regression, VS = Stromal cells from vehicle-treated mice, and CS = Stromal cells
from chemo-treated mice at regression. Tumor size of .50 mm3 was considered as positive for tumor growth.
doi:10.1371/journal.pone.0045647.t002
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identified several in vivo xenograft models that show tumor
regression or stasis followed by relapse in response to standard-
of-care chemotherapeutic agents (Fig. 1A). We used GFP-
expressing sublines of the Calu3, H441 and H596 human NSCLC
xenograft models. Established tumor bearing mice were treated
with either vehicle or the maximum tolerated dose of a
combination regimen of paclitaxel and cisplatin. Following
completion of treatment, tumor volumes in chemo-treated mice
were similar to (H596) or smaller than (Calu3, H441) the volume
at study start (Fig. 1B–D). Regression persisted for several weeks
after the last dose of chemotherapy but all tumors subsequently
recurred (Fig. 1B–D). In addition, we used the LSL-K-
rasG12D;p53Fl/Fl genetically engineered mouse model (GEMM) of
NSCLC [21] crossed to a RFP Cre-reporter strain [22]. Cisplatin
treatment of LSL-K-rasG12D;p53Fl/Fl mice prolongs survival but
mice still rapidly succumb to their disease indicating that tumors
initially respond to therapy but resume growing after treatment
[23].
Although each of the models used responded to chemotherapy,
the tumors relapsed at varying times after therapy even when there
was nearly complete cytoreduction. We next sought to isolate the
GFP- or RFP-labeled tumor cells that survived after chemotherapy
but prior to the onset of tumor re-growth, since these cells by
definition are enriched for the TRIC population. In each of the 3
xenograft models the number and proportion of GFP+ tumor cells
present in chemo-treated animals was significantly lower than in
vehicle-treated control mice (Fig. 1E) indicating that only a small
proportion of tumor cells survive after chemotherapy.
Characterization of TRICs for Cancer Stem Cell Phenotype
To determine the expression of known CSCs markers in
TRICs, we carried out in vivo studies as described above and used
flow cytometry to analyze the proportion of GFP+ tumor cells in
residual and vehicle-treated tumors that express the previously
reported NSCLC CSC markers, CD133, CD44 and CD117. The
proportion of CD133+ and CD44+ tumor cells varied greatly
between models (Fig. 2A), consistent with the wide variation in the
proportion of positive cells between tumors noted in the original
publications identifying each of these CSC markers [24,25]. In the
H441 model (Fig. 2A), there was a robust increase in CSC marker
positive tumor cells with a ,3-fold increase in CD44+ cells, a
12.5-fold increase in CD133+ cells and a 5-fold increase in
CD117+ cells (Fig. 2A). In contrast, in the Calu3 model there was
a modest but significant increase in the proportion of CD44+
tumor cells, a significant decrease in the proportion of CD133+
tumor cells and no change in the proportion of CD117+ cells in
tumors from chemo-treated mice. Results were also mixed in the
H596 model (Fig. 2A), with a significant decrease in the proportion
of CD44+ cells, an increase in CD133+ cells and no significant
change in CD117+ tumor cells. Thus, using previously described
CSC markers we did not observe the consistent enrichment of a
specific tumor cell population.
To further explore whether the cells mediating tumor relapse
are indeed CSCs, we assessed the tumor-initiating capacity of
TRICs. We were unable to determine the tumorigenicity of
these cells using sphere assays, since cells from vehicle and
chemo-treated Calu3, H441 or H596 tumors failed to generate
spheres after being grown in vivo, despite robust sphere
formation from the parental and GFP-stable cell lines under
identical conditions.
Next, we conducted transplantation assays to assess the tumor-
initiating capacity of TRICs isolated from the Calu3, H441 and
H596 xenograft models and the LSL-K-rasG12D;p53Fl/Fl GEMM.
Surprisingly, for both the Calu3 and H441 models, tumor cells
isolated from vehicle-treated mice were more efficient at tumor
initiation than tumor cells from chemo-treated mice (Fig. 2B–C,
Table 1). Although the incidence of tumor formation from H441
vehicle- and chemo-treated cells was similar, the growth of the
vehicle-treated tumor cells was considerably more robust as
demonstrated by the significantly larger average tumor volume. In
contrast, tumor cells isolated from chemo-treated H596 tumors
were significantly more tumorigenic than cells isolated from
vehicle-treated tumors (Fig. 2D, Table 1). Here again, tumor
incidence was similar between vehicle- and chemo-treated tumor
cells, but tumors derived from vehicle-treated tumor cells were
significantly larger. There was no significant difference in the
tumor initiating potential of LSL-K-rasG12D;p53Fl/Fl GEMM tumor
cells isolated from chemo- or vehicle-treated mice upon orthotopic
grafting via intratracheal intubation (Fig. 2E, Table 1). Thus,
TRICs are not consistently enriched for CSCs. Furthermore, the
results of the transplantation studies showed no correlation
between tumor initiating capacity and the expression of CSCs
markers. TRICs isolated from the H441 model were enriched for
all CSCs markers (Fig. 2A) but did not show increased tumor
initiating potential, while TRICs isolated from the H596 model
demonstrated increased tumor initiating potential but were only
enriched for CD133 expression (Fig. 2A).
Histological examination and FACS analysis of vehicle-treated
and regressed tumors revealed dramatic differences in the
amount of stroma between models, and between vehicle and
regressed tumors within a given model (Fig. 3A–B). Further-
more, the size of the stromal component in the residual tumors
was inversely correlated with tumor initiating potential of the
TRICs. Of the 3 models, residual H596 tumors contained the
least stroma and H596 TRICs were significantly more
tumorigenic than cells from vehicle-treated mice. In contrast,
residual Calu3 and H441 tumors were comprised mainly of
stroma and TRICs isolated from these tumors were limited in
their tumor initiating capacity upon transplantation. We
reasoned that lack of stromal support could explain why TRICs
readily re-grew tumors in the original host but showed
decreased tumorigenicity upon transplantation. To determine
if TRIC growth was dependent on stromal-derived factors, we
performed transplantation studies in the presence of stromal
cells. We isolated four different cell fractions from tumors from
chemotherapy or vehicle-treated mice by FACS sorting (Fig. 4A):
(1) GFP+ tumor cells from chemo-treated mice at regression
(CT), (2) GFP- stromal cells from chemo-treated mice at
regression (CS), (3) GFP+ tumor cells from vehicle-treated mice
(VT), and (4) GFP- stromal cells from vehicle-treated mice (VS).
We mixed tumor and stromal cells and transplanted the
mixtures into naı¨ve host mice. In the Calu3 model neither
VS nor CS cells provided a growth benefit to VT or CT cells,
and as observed earlier, VT cells were more tumorigenic than
CT cells when implanted alone (Fig. 4B, Table 2). There was a
significant growth advantage for VT cells from the H441 model
when they were implanted with either VS or CS but CT cells
Figure 3. Increased Stromal Component in Residual Chemotherapy-Treated Tumors. A) Masson’s Trichrome staining of vehicle and
regressed chemo-treated tumors showing a decrease in tumor cells (red) and an increase in collagen-containing stromal cells (blue) in residual
tumors. B) FACS analysis of vehicle and regressed tumors showing a decreased tumor:stroma ratio in residual tumors.
doi:10.1371/journal.pone.0045647.g003
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were still much less tumorigenic than VT cells even when
mixed with stroma (Fig. 4C, Table 2). Of note, the tumor-
initiating potential of the TRICs in the transplantation assay
was not fully consistent between experiments. Transplantation of
5,000 Calu3 TRICs did not result in tumor formation in any of
the grafted animals in the previous study (Fig. 2B and Table 1)
but generated tumors in 44% of recipients in this study (Fig. 4B,
Table 2). The results of H441 TRIC transplants were also
inconsistent, with TRICs generating tumors in the previous
study but not in this one (Fig. 2C, Table 1 and Fig. 4C, Table 2
respectively). These results suggest that small variations in
experimental conditions could dramatically affect tumor-initiat-
ing potential upon transplantation. However, in both experi-
ments Calu3 and H441 TRICs were less tumorigenic than
tumor cells from vehicle-treated mice, demonstrating that
TRICs are not consistently enriched for CSCs as evidenced
by standard transplantation assay.
Characterization of TRICs for EMT Phenotype
Emerging evidence suggests that tumor cells undergoing EMT
have an increased capacity for chemoresistance, metastasis and
tumor relapse [26–28]. EMT has also been shown to confer cancer
stem cell properties in breast, colon and pancreatic cancers
[18,29]. Therefore, we studied TRICs for EMT characteristics.
We assessed the expression of markers and regulators of EMT in
TRICs and vehicle-treated tumor cells by qRT-PCR. There was a
significant increase in the expression of mesenchymal markers and
EMT-inducing transcription factors in residual tumor cells
(Fig. 5A). In addition, we also collected tumor specimens for
histological analysis at regression and relapse. Immunofluores-
cence analysis of these specimens corroborated the qRT-PCR
results. There was a significant increase in the proportion of
Vimentin expressing tumor cells and significant decrease in the
proportion of E-Cadherin expressing tumor cells in regressed
tumors compared to tumors from vehicle-treated mice (Fig. 5B–C).
The proportions in relapsed tumors were similar to the vehicle-
treated tumors demonstrating the plasticity of the TRICs.
Together, these results demonstrate that TRICs are in an EMT
state.
To further assess whether chemotherapy treatment induces the
expression of EMT-inducing transcription factors or selects for a
population of cells that are in an EMT state, we conducted a time
course analysis. We found that the onset of enrichment of EMT-
inducing transcription fractors in cells treated with chemotherapy
in vitro coincides with the onset of cell death, and shows additional
enrichment as additional cells are lost from the cultures (Fig. 5D–
E). These data suggest that chemotherapy is indeed selecting for a
population of cells in EMT.
Discussion
In the cancer stem cell model of tumorigenesis, a small subset
of cancer cells has the unique capacity to propagate the tumor
due to their exclusive ability to self-renew and to generate
progeny that differentiate into the heterogenous non-tumorigen-
ic cell types that make up the bulk of the tumor [1].
Furthermore, several studies have shown that CSCs have
increased resistance to conventional chemo- and radio-therapies
[6,30,31]. The CSC hypothesis has received key attention
because it provides a possible explanation for the processes of
disease relapse after therapy [32]. However, because CSCs have
been defined by transplantation assays, the roles of CSCs in
maintaining an established tumor and in disease relapse within
the original host remain to be determined. In this notion, we
utilized several in vivo preclinical models treated with standard of
care chemotherapy agents [33] to characterize the cells
responsible for tumor relapse, TRICs. By utilizing models that
regress in response to chemotherapy and models that undergo
stasis, we aimed to reflect the different responses of NSCLC
patients to chemotherapy. We isolated and evaluated them for
several properties commonly used to define CSCs.
Numerous publications regarding the use of self-surface
markers to identify NSCLC CSCs report conflicting results.
For example, CD133+ cells from NSCLC cell lines and primary
patient samples have been reported to have the unique ability
to generate spheres in vitro and to initiate tumors in immuno-
compromised mice [12,13,16,17,34]. In contrast, others report
that both the CD133+ and CD133- cells display similar colony
formation, self-renewal, proliferation, differentiation, invasion,
chemoresistance and tumorigenicity [14,16]. Furthermore,
CD133 expression showed no correlation with disease-free or
overall survival of NSCLC patients. [17]. The use of CD44 to
identify NSCLC CSCs has generated similar conflicting results
[15]. We, too, saw inconsistent enrichment of these putative
CSC markers in residual tumor cells from multiple models.
Moreover, even in models where the proportion of CD133+ or
CD44+ cells is enriched, the TRICs do not have an enhanced
tumor initiating capacity.
Because the use of cell surface markers for the prospective
identification of CSCs from NSCLCs has yielded conflicting
results, we also compared the tumor initiating potential of TRICs
vs. vehicle-treated tumor cells from xenograft and GEM models.
However, TRICs from only one xenograft model were enriched
for tumor initiating potential. It is important to note that when left
undisturbed within the original host TRICs consistently caused
tumor recurrence after chemotherapy in all of the models we
studied, even in rare instances when no palpable tumor was
present after treatment. Consistent with our findings, Yan and
colleagues recently reported that in vitro-derived, drug-tolerant
cancer cell lines are less proliferative than their parental cell lines
and have reduced cloning efficiency and tumor-initiating capacity
[35].
We found that the majority of cells present in the residual
tumors were not cancer cells, but rather stromal cells. Recent
work by Gilbert and Hemann demonstrated that chemotherapy
induces the release of paracrine factors from tumor-associated
stromal cells modulating tumor cell survival [36]. We reasoned
that the lack of necessary stromal support could explain why the
transplantation of TRICs to a new host significantly decrease
their tumorigenicity. Therefore, we assessed whether vehicle and
chemo-treated stromal cells (VS and CS respectively) could
enhance tumor initiating potential in mixing experiments. We
did find that stromal cells enhanced the tumor initiating
potential of both vehicle and chemo-treated H441 cells.
Figure 4. Effect of Stroma on Tumor Initiating Potential of TRICs in transplanation assays. A) Representative FACS plots showing gates
used for sorting GFP+ tumor and stromal cells from Calu3 (left) and H441 tumors (right). B) Calu-3 and C) H441 tumor (GFP+) and stromal (GFP-) cells
were isolated from tumors taken from vehicle or chemo-treated mice at tumor regression. Tumor and stromal cells were mixed as indicated and
grafted subcutaneously into athymic nude mice. Graphs show individual tumor volumes at the end of study, bars indicate the average tumor volume
per group. See Table 2 for further details.
doi:10.1371/journal.pone.0045647.g004
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However, this property of the stromal cells was independent of
chemotherapy treatment since both VS and CS cells augmented
tumor growth to a similar degree. Moreover, H441 TRICs were
still less tumorigenic than cells isolated from vehicle-treated
tumors, and TRICs from Calu3 tumors still had very little
tumor initiating capacity even when mixed with stroma. This
suggests that maintenance of the complex cell-cell and cell-
extracellular matrix interactions present in regressed tumors is
required for tumor regrowth to occur. Thus, our data caution
about relying on classic CSC transplantation assays as a read
out of disease relapse.
The EMT state has been linked to resistance to both
conventional and targeted therapeutics in a variety of cancer
cell lines [37–41]. We also found that TRICs are in an EMT
state as evidenced by decreased expression of E-cadherin and
increased expression of mesenchymal markers and EMT-
inducing transcription factors. Thus, the EMT state of the
TRICs likely contributes to their ability to withstand chemo-
therapy treatment. Interestingly, Mani et al. recently reported
that induction of EMT in transformed mammary epithelial cells
converts differentiated tumor cells into CSCs [18], and
induction of EMT by TGF-beta was also shown to increase
the stemness characteristic of NSCLC cells in vitro [27,42,43].
However, despite the EMT state of the TRICs, we did not find
evidence of increased stemness, indicating that EMT may
contribute to chemoresistance in a manner that is independent
of its ability to confer stemness.
In conclusion, we show here that residual tumor cells that
survive chemotherapy and cause disease relapse are in an EMT
state but do not consistently demonstrate increased CSC marker
expression or tumor initiating capacity. Our results indicate that
while the analysis of known CSC markers, and the use of classical
transplantation assays clearly identify tumor cells with unique and
important characteristics, they may not truly identify the subset of
tumor cells responsible for recurrence after chemotherapy. Rather
these cells must be identified based on their abilities to withstand
chemotherapy and re-initiate tumor growth. Further analysis of
the cells that have been functionally defined as TRICs will likely
yield novel insights into the drivers of chemoresistance and disease
recurrence.
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